BerandaPHS • FRA
add
Photocure ASA
Tutup sebelumnya
€4,46
Rentang hari
€4,42 - €4,42
Rentang tahun
€3,97 - €5,63
Volume Rata-Rata
13,00
Rasio P/E
-
Hasil dividen
-
Berita pasar
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
(NOK) | Mar 2025info | Perubahan Y/Y |
---|---|---|
Pendapatan | 125,34Â jt | 6,18% |
Biaya operasional | 121,77Â jt | 11,16% |
Laba bersih | -2,41Â jt | 69,44% |
Margin laba bersih | -1,92 | 71,26% |
Penghasilan per saham | -0,09 | 68,97% |
EBITDA | 318,00Â rb | -95,96% |
Tarif pajak efektif | 74,31% | — |
Neraca
Total aset
Total liabilitas
(NOK) | Mar 2025info | Perubahan Y/Y |
---|---|---|
Investasi tunai jangka pdk | 259,54Â jt | 0,49% |
Total aset | 708,56Â jt | -0,85% |
Total liabilitas | 236,71Â jt | 2,24% |
Total ekuitas | 471,85 jt | — |
Saham yang beredar | 26,65 jt | — |
Harga terhadap nilai buku | 0,25 | — |
Tingkat pengembalian aset | -1,93% | — |
Tingkat pengembalian modal | -2,81% | — |
Arus Kas
Perubahan kas bersih
(NOK) | Mar 2025info | Perubahan Y/Y |
---|---|---|
Laba bersih | -2,41Â jt | 69,44% |
Kas dari operasi | 4,07Â jt | -51,46% |
Kas dari investasi | 657,00Â rb | 303,07% |
Kas dari pembiayaan | -39,04Â jt | -299,12% |
Perubahan kas bersih | -34,31Â jt | -2.682,81% |
Arus kas bebas | 8,38Â jt | 15,47% |
Tentang
Photocure ASA is a Norwegian specialty pharma company that develops and sells pharmaceuticals and medical devices based on proprietary photodynamic technology. Photocure's strategy in cancer is to continue the commercialization of Hexvix for bladder cancer diagnostics, and continue the development of the cancer portfolio and out-license prior to phase III studies. This strategy is based on a strong platform of intellectual property in photodynamic therapy. Wikipedia
Didirikan
1993
Situs
Karyawan
100